US guidelines urge more cholesterol meds than Europe

Image
AFP Washington
Last Updated : Mar 30 2014 | 12:05 AM IST
US guidelines for prescribing cholesterol-lowering drugs to people over 55 call for many more to be taking the medications than in Europe, researchers said today.
The findings raised new questions about how popular drugs like Lipitor (atorvastatin) and Zocor (simvastatin) are prescribed and to whom, after new US guidelines issued in November called for more adults without heart disease to start taking the medications in order to prevent future health problems.
Nearly every man and most women in a study of nearly 5,000 healthy people over age 55 in The Netherlands would be prescribed some sort of statin under US guidelines, said the study in the Journal of the American Medical Association.
About 96 percent of men and 66 percent of women in the Rotterdam study would be urged to take a statin, according to guidelines from the American College of Cardiology and the American Heart Association.
Far fewer would under guidelines from the European Society of Cardiology. Just 66 percent of men and 39 percent of women were included in the category where treatment was recommended.
The gap comes down to how the guidelines account for the risk of cardiovascular disease in the coming 10 years, resulting in "substantial differences in proportions of individuals qualifying for treatment at a population level," said the study, led by Maryam Kavousi of Erasmus MC-University Medical Center.
Statins can help prevent heart disease by lowering cholesterol in the blood and keeping the heart and arteries free of plaque buildup that can lead to stroke or heart attack.
Currently, some 25 million Americans take statins.
The new American Heart Association guidelines mean 56 million people in the United States may be candidates for the drug therapy, up from 43 million under the previous 2001 guidelines, according to research published earlier this month.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 30 2014 | 12:05 AM IST

Next Story